Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. is an AI-driven allogeneic cell therapy company specializing in developing multi-indication allogeneic T cell therapies targeting solid tumors. Their product candidates include ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy targeting PD-L1. The company generates revenue through the development and potential commercialization of these innovative cell therapy products, leveraging strategic alliances and research collaborations to advance their pipeline and bring novel treatments to market.

Products

• ALEXIS-ISO-1 (allogenic gamma delta CAR-T cell therapy)

• ALEXIS-PRO-1 (allogeneic gamma delta chimeric T cell therapy)